GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Beijing Strong Biotechnologies Inc (SZSE:300406) » Definitions » Capex-to-Operating-Income

Beijing Strong Biotechnologies (SZSE:300406) Capex-to-Operating-Income : 0.26 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Beijing Strong Biotechnologies Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Beijing Strong Biotechnologies's Capital Expenditure for the three months ended in Mar. 2024 was ¥-39.39 Mil. Its Operating Income for the three months ended in Mar. 2024 was ¥154.13 Mil.

Hence, Beijing Strong Biotechnologies's Capex-to-Operating-Income for the three months ended in Mar. 2024 was 0.26.


Beijing Strong Biotechnologies Capex-to-Operating-Income Historical Data

The historical data trend for Beijing Strong Biotechnologies's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Strong Biotechnologies Capex-to-Operating-Income Chart

Beijing Strong Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.09 0.11 0.18 0.23

Beijing Strong Biotechnologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.26 0.20 0.21 0.26

Competitive Comparison of Beijing Strong Biotechnologies's Capex-to-Operating-Income

For the Diagnostics & Research subindustry, Beijing Strong Biotechnologies's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Strong Biotechnologies's Capex-to-Operating-Income Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Beijing Strong Biotechnologies's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Beijing Strong Biotechnologies's Capex-to-Operating-Income falls into.



Beijing Strong Biotechnologies Capex-to-Operating-Income Calculation

Beijing Strong Biotechnologies's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-148.032) / 649.302
=0.23

Beijing Strong Biotechnologies's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-39.385) / 154.125
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Strong Biotechnologies  (SZSE:300406) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Beijing Strong Biotechnologies Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Beijing Strong Biotechnologies's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Strong Biotechnologies (SZSE:300406) Business Description

Traded in Other Exchanges
N/A
Address
No. 15 Hua Yuan Dong Lu, 5th Floor, Kuang Yi Building, Haidian District, Beijing, CHN, 100191
Beijing Strong Biotechnologies Inc is a China-based provider of in-vitro (IVD) diagnostics products and service. The company is engaged in the research, development, production, and sale of IVD products. It also provides diversified clinical diagnosis solutions to customers. Its products include clinical biochemistry testing, coagulation testing, blood typing, serology and automated blood grouping analyzer. The firm has established a clinical biochemistry platform of the enzymatic method (including enzymatic cycling method), immunoturbidimetric method, and latex immunoturbidimetric method.
Executives
Shuang He Executives
Luo Ai Ping Director
Directors, executives
Liu Wei Executives
Zhou Ming Executives
Zhuang Xian Min Directors, executives
Zhang Yi Executives
Liu Xi Directors, executives
Sun Xiao Lin Director
Yu Jian Ping Executives

Beijing Strong Biotechnologies (SZSE:300406) Headlines

No Headlines